These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 23407481)

  • 1. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
    Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
    Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
    Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.
    Prokopchuk O; Grünwald B; Nitsche U; Jäger C; Prokopchuk OL; Schubert EC; Friess H; Martignoni ME; Krüger A
    BMC Cancer; 2018 Feb; 18(1):128. PubMed ID: 29394913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
    Kendrick ZW; Firpo MA; Repko RC; Scaife CL; Adler DG; Boucher KM; Mulvihill SJ
    HPB (Oxford); 2014 Jul; 16(7):670-6. PubMed ID: 24308545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin expression and serum levels in pancreatic cancer.
    Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
    World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.
    Kolb A; Kleeff J; Guweidhi A; Esposito I; Giese NA; Adwan H; Giese T; Büchler MW; Berger MR; Friess H
    Cancer Biol Ther; 2005 Jul; 4(7):740-6. PubMed ID: 15970685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.
    Jenkinson C; Elliott V; Menon U; Apostolidou S; Fourkala OE; Gentry-Maharaj A; Pereira SP; Jacobs I; Cox TF; Greenhalf W; Timms JF; Sutton R; Neoptolemos JP; Costello E
    J Proteomics; 2015 Jan; 113():400-2. PubMed ID: 25316052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.